Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings Inc (CRBP) Covered Calls
Corbus Pharmaceuticals Holdings Inc trades in the Biotechnology industry with an IV Rank of 78.17%, high versus the past year. CRBP's highest covered call setup is the $10.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 195.86% out of the money with 123 days to expiration, a 197.34% return until expiration, and a 585.59% theoretical annualized return. Across the setups shown, annualized returns run from 226.10% to 585.59% at strikes between $4.00 and $10.00, with 32 to 123 days to expiration, as of Nov 16, 2026.
Read more
Running CRBP covered calls helps you generate income from Corbus Pharmaceuticals Holdings Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CRBP covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CRBP stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRBP covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CRBP covered call is worth writing.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
| 2027-03-19 | 123 | 10.00 | 195.86 | 0.05 | 2.85 | 667.00 | 197.34 | 585.59 | -1.48 | +0.62 | 492 | 2.80 |
| 2027-03-19 | 123 | 7.50 | 121.89 | 0.05 | 2.00 | 417.00 | 123.37 | 366.11 | -1.48 | +0.53 | 515 | 1.95 |
| 2026-12-18 | 32 | 4.00 | 18.34 | 0.05 | 1.15 | 67.00 | 19.82 | 226.10 | -1.48 | +0.51 | 4 | 1.10 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank78.17% High
- Market cap (M$)50
- 52 weeks high-81.06%
- 52 weeks low-6.87%
- Analyst recommendationStrong Buy
1.00 - Target price$31.12
1175.41% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-6.09
- EPS growth next 5 years4.68%
As of Nov 19, 2026